Defining Models to Classify between Benign and Malignant Adnexal Masses Using Routine Laboratory Parameters

Elisabeth Reiser; Dietmar Pils; Christoph Grimm; Ines Hoffmann; Stephan Polterauer; Marlene Kranawetter; Stefanie Aust

doi:10.3390/cancers14133210

Defining Models to Classify between Benign and Malignant Adnexal Masses Using Routine Laboratory Parameters

Cancers (Basel). 2022 Jun 30;14(13):3210. doi: 10.3390/cancers14133210.

Authors

Elisabeth Reiser¹, Dietmar Pils², Christoph Grimm³, Ines Hoffmann³, Stephan Polterauer³, Marlene Kranawetter³, Stefanie Aust³

Affiliations

¹ Department of Gynecological Endocrinology and Reproductive Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.
² Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria.
³ Department of Gynecology and Gynecologic Oncology, Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090 Vienna, Austria.

Abstract

Discrimination between benign and malignant adnexal masses is essential for optimal treatment planning, but still remains challenging in a routine clinical setting. In this retrospective study, we aimed to compare albumin as a single parameter to calculate models by analyzing laboratory parameters of 1552 patients with an adnexal mass (epithelial ovarian cancer (EOC): n= 294; borderline tumor of the ovary (BTO): n = 66; benign adnexal mass: n = 1192) undergoing surgery. Models comprising classical laboratory parameters show better accuracies (AUCs 0.92-0.93; 95% CI 0.90-0.95) compared to the use of single markers, and could easily be implemented in clinical practice by containing only readily available markers. This has been incorporated into a nomogram.

Keywords: BTO; adnexal mass; benign cyst; classification; model; ovarian cancer.

Grants and funding

This research received no external funding.